Email updates

Keep up to date with the latest news and content from BMC Bioinformatics and BioMed Central.

This article is part of the supplement: UT-ORNL-KBRIN Bioinformatics Summit 2012

Open Access Meeting abstract

The effects of early-life risperidone administration on forebrain neurotrophin expression during adulthood

Matt Gannon, Rachel Stevens, Molly Griffith and Mark Bardgett*

Author affiliations

Department of Psychological Science, Northern Kentucky University, Highland Heights, KY 41076, USA

For all author emails, please log on.

Citation and License

BMC Bioinformatics 2012, 13(Suppl 12):A19  doi:10.1186/1471-2105-13-S12-A19


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2105/13/S12/A19


Published:31 July 2012

© 2012 Gannon et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

The antipsychotic drug risperidone has become increasingly popular as a treatment for children with various behavioral disorders, including autism. However, little is known about the long-term effects of early-life risperidone treatment on the brain and behavior. The frontal cortex is one of the primary targets of risperidone action in the brain, so the purpose of this study was to determine if early-life risperidone treatment altered neurotrophin expression in the prefrontal cortex during adulthood.

Materials and methods

Twenty-four rats (13 females, 11 males) received daily injections from postnatal days 14-42. Rats were divided into two treatment groups (1.0 and 3.0 mg/kg risperidone) and a vehicle control. Brain tissue was collected on postnatal day 62. Prefrontal cortical tissue from the left hemisphere was examined for neurotrophin expression through the use of a rat neurotrophin RT-PCR array kit (SABiosciences, Inc.). Sections of prefrontal cortex were also used for immunohistochemistry.

Results

PCR results indicated an up-regulation of mRNA for the cytokine, Leukemia Inhibitory Factor (LIF), in the low and high dose treatment groups. Immunohistochemistry is being conducted to assess possible differences in LIF protein levels in the prefrontal cortex of the different treatment groups.

Conclusion

This study indicates that early-life risperidone treatment has the potential to alter the expression of proteins involved in cell growth and differentiation with brain regions critical for cognitive control. The behavioral consequences of these cellular changes are an area that further research should address.

Acknowledgements

This work was supported by grants from the National Center for Research Resources (5P20RR016481), National Institute of Mental Health (1R15MH094955), and the Center for Integrated Natural Sciences and Mathematics at Northern Kentucky University.